Zacks: Analysts Anticipate LivaNova PLC (LIVN) Will Post Quarterly Sales of $274.10 Million
Equities analysts predict that LivaNova PLC (NASDAQ:LIVN) will post $274.10 million in sales for the current quarter, Zacks reports. Three analysts have issued estimates for LivaNova’s earnings, with estimates ranging from $271.50 million to $276.30 million. LivaNova posted sales of $287.50 million during the same quarter last year, which suggests a negative year-over-year growth rate of 4.7%. The firm is scheduled to announce its next earnings results on Wednesday, August 7th.
On average, analysts expect that LivaNova will report full-year sales of $1.11 billion for the current year, with estimates ranging from $1.10 billion to $1.11 billion. For the next year, analysts forecast that the firm will report sales of $1.18 billion, with estimates ranging from $1.16 billion to $1.19 billion. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research analysts that cover LivaNova.
LivaNova (NASDAQ:LIVN) last released its earnings results on Wednesday, May 1st. The company reported $0.54 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $0.43 by $0.11. LivaNova had a negative net margin of 19.64% and a positive return on equity of 9.38%. The business had revenue of $250.80 million for the quarter, compared to analysts’ expectations of $254.89 million. During the same period last year, the company earned $0.68 earnings per share. The company’s quarterly revenue was up .2% on a year-over-year basis.
In other LivaNova news, Director Daniel Jeffrey Moore sold 1,500 shares of LivaNova stock in a transaction that occurred on Friday, March 15th. The shares were sold at an average price of $96.63, for a total transaction of $144,945.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, Director Alfred J. Novak sold 1,300 shares of LivaNova stock in a transaction that occurred on Thursday, May 9th. The shares were sold at an average price of $70.63, for a total transaction of $91,819.00. The disclosure for this sale can be found here. Insiders own 0.41% of the company’s stock.
Hedge funds have recently made changes to their positions in the business. BlackRock Inc. lifted its position in shares of LivaNova by 2.2% during the fourth quarter. BlackRock Inc. now owns 5,915,599 shares of the company’s stock worth $541,101,000 after purchasing an additional 127,669 shares in the last quarter. Morgan Stanley lifted its position in shares of LivaNova by 36.2% during the first quarter. Morgan Stanley now owns 2,123,555 shares of the company’s stock worth $206,516,000 after purchasing an additional 563,905 shares in the last quarter. Wells Fargo & Company MN lifted its position in shares of LivaNova by 2.4% during the first quarter. Wells Fargo & Company MN now owns 1,185,295 shares of the company’s stock worth $115,271,000 after purchasing an additional 27,772 shares in the last quarter. Vanguard Group Inc. lifted its position in shares of LivaNova by 6.8% during the third quarter. Vanguard Group Inc. now owns 1,083,237 shares of the company’s stock worth $134,289,000 after purchasing an additional 68,637 shares in the last quarter. Finally, Northern Trust Corp lifted its position in shares of LivaNova by 1.4% during the first quarter. Northern Trust Corp now owns 774,446 shares of the company’s stock worth $75,315,000 after purchasing an additional 10,729 shares in the last quarter. 88.52% of the stock is currently owned by hedge funds and other institutional investors.
LIVN opened at $71.88 on Monday. The company has a debt-to-equity ratio of 0.13, a quick ratio of 0.61 and a current ratio of 0.87. LivaNova has a 1 year low of $64.80 and a 1 year high of $131.54. The company has a market capitalization of $3.55 billion, a P/E ratio of 22.68, a P/E/G ratio of 3.09 and a beta of 0.71.
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates in two segments, Cardiovascular (CV) and Neuromodulation (NM). The CV segment develops, produces, and sells cardiopulmonary products, including heart-lung machines, oxygenators, perfusion tubing sets, cannulae, and accessories, as well as related equipment and disposables for autotransfusion and autologous blood washing for neonatal, pediatric, and adult patients.
Featured Article: Channel Trading
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.